Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

B-cell receptor–mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma

Li Li, Jun Zhang, Juan Chen, Zijun Y. Xu-Monette, Yi Miao, Min Xiao, Ken H. Young, Sa Wang, L. Jeffrey Medeiros, Michael Wang, Richard J. Ford, Lan V. Pham

Blood (2018) 132 (17): 1805–1817.

https://doi.org/10.1182/blood-2018-03-841015

Published: 2018

Includes: Supplemental data

Journal Articles

Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results

Jason R. Westin, MD, Yasuhiro Oki, MD, Loretta Nastoupil, MD, Luis Fayad, MD, Sattva S. Neelapu, MD, Francesco Turturro, MD, F. B. Hagemeister, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, MD, Ken H. Young, MD PhD, Timothy J. McDonnell, MD PhD, Richard J. Ford, MD PhD, R. Eric Davis, MD

Blood (2017) 130 (Supplement 1): 189.

https://doi.org/10.1182/blood.V130.Suppl_1.189.189

Published: 2017

Journal Articles

Cannabinoid Receptor Signaling As a Target for Personalized Therapy in Aggressive B Cell Lymphomas

Lan Pham, PhD, Juan Chen, PhD, Archie Tamayo, MS, Jerry Bryant, David Yang, PhD, Richard J. Ford, Jr., MD PhD

Blood (2016) 128 (22): 4181.

https://doi.org/10.1182/blood.V128.22.4181.4181

Published: 2016

Journal Articles

Preclinical Evaluation of the Oral Proteasome Inhibitor Ixazomib in Diffuse Large B-Cell Lymphoma

Wei Liu, MD, Archie Tamayo, MS, Juan Chen, PhD, Shimin Hu, PhD MD, Richard J. Ford, Jr., MD PhD, Lan Pham, PhD

Blood (2015) 126 (23): 4003.

https://doi.org/10.1182/blood.V126.23.4003.4003

Published: 2015

Journal Articles

The Tumor Microenvironment in Mantle Cell Lymphoma (MCL): Novel Targets to Overcome Chemo-Resistance in MCL

Lan V Pham, PhD, Archito T. Tamayo, MS, Elizabeth Pogue, Gary Lu, MD, Pramoda Challagundla, Jeffrey L. Jorgensen, MD PhD, Liang Zhang, MD PhD, Michael Wang, MD, Richard J. Ford, MD PhD

Blood (2014) 124 (21): 494.

https://doi.org/10.1182/blood.V124.21.494.494

Published: 2014

Journal Articles

STAT3 Activation Is Preceded By Two Independent Pathways (BCR-BTK and IL6-JAK) in Mantle Cell Lymphoma

Hyebin Park, Donglu Zhao, George Tsourdinis, Zhishuo Ou, MD, Archito T. Tamayo, MS, Richard J. Ford, MD PhD, Bingliang Fang, MD PhD, Lan V Pham, PhD, Liang Zhang, MD PhD, Michael Wang, MD

Blood (2014) 124 (21): 3028.

https://doi.org/10.1182/blood.V124.21.3028.3028

Published: 2014

Journal Articles

Anti-CD20 and B-Cell Receptor-Mediated Growth Inhibition and Apoptosis: A Preclinical Study of Ibrutinib and Rituximab Combination Therapy in Mantle Cell Lymphoma in Vitro and in Vivo

Liang Zhang, MD PhD, Hui Zhang, Donglu Zhao, MD, George Tsourdinis, Hyebin Park, Archito T. Tamayo, MS, Lan V Pham, PhD, Richard J Ford, MD, Bingliang Fang, MD PhD, Michael Wang, MD

Blood (2014) 124 (21): 1774.

https://doi.org/10.1182/blood.V124.21.1774.1774

Published: 2014

Journal Articles

Carfilzomib, a Second-Generation Proteasome Inhibitor, In Combination With The Btk Inhibitor Ibrutinib As a Novel Therapeutic Regimen For Treating Double Hit DLBCL

Erin M Dominici, Elyse R Lopez, Muychi T Vang, Archito T. Tamayo, MS, Zhishuo Ou, MD, Alex Rollo, Liang Zhang, MD, PhD, Jack Wang, Lauren M Strickland, Michael Wang, MD, Richard J. Ford, MD, PhD, Lan V Pham, PhD, Christopher J. Kirk, Ph.D

Blood (2013) 122 (21): 1834.

https://doi.org/10.1182/blood.V122.21.1834.1834

Published: 2013

Journal Articles

Ibrutinib Overcomes Carfilzomib Resistance In Immunoproteasome-Deficient Mantle Cell Lymphoma

Liang Zhang, MD, PhD, Zhishuo Ou, MD, Jack Wang, Erin M Dominici, Hui Zhang, Richard J. Ford, Jr., MD, PhD, Michael Wang, MD, Lan V Pham, PhD

Blood (2013) 122 (21): 3074.

https://doi.org/10.1182/blood.V122.21.3074.3074

Published: 2013

Journal Articles

Targeting BCR Activated STAT3 By Ibrutinib In Mantle Cell Lymphoma

Zhishuo Ou, MD, Lan V Pham, PhD, Muychi T Vang, Liang Zhang, MD, PhD, Jack Wang, Lauren M Strickland, Elyse R Lopez, Erin M Dominici, Alex Rollo, Archito T. Tamayo, MS, Richard J. Ford, MD, PhD, Michael Wang, MD

Blood (2013) 122 (21): 3079.

https://doi.org/10.1182/blood.V122.21.3079.3079

Published: 2013

Journal Articles

Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)

L. Kyle Brett, MD, Mark Axelrod, PhD, Zhishuo Ou, MD, Liang Zhang, MD, PhD, Vicki Gordon, BS, Elyse R Lopez, Archito T. Tamayo, MS, Richard J. Ford, MD, PhD, Lan V Pham, PhD, Michael J. Weber, PhD, Michael E. Williams, MD, ScM, Michael Wang, MD

Blood (2013) 122 (21): 3080.

https://doi.org/10.1182/blood.V122.21.3080.3080

Published: 2013

Journal Articles

Selective Inhibitor Of Nuclear Exports (SINE) KPT-330 In Combination With The Novel Proteasome Inhibitor Carfilzomib As a Novel Therapeutic Regimen For Treating Aggressive B-Cell Lymphomas

Elyse R Lopez, Erin M Dominici, Muychi T Vang, Archito T. Tamayo, MS, Zhishuo Ou, MD, Alex Rollo, Liang Zhang, MD, PhD, Jack Wang, Lauren M Strickland, Christopher J. Kirk, Ph.D, Michael Kauffman, MD, PhD, Sharon Shacham, PhD, MBA, Michael Wang, MD, Lan V Pham, PhD, Richard J. Ford, MD, PhD

Blood (2013) 122 (21): 5147.

https://doi.org/10.1182/blood.V122.21.5147.5147

Published: 2013

Journal Articles

The Role Of Mir-155 In Controlling Key Growth and Survival Pathways In ABC-Subtype DLBCL

Lan V Pham, PhD, Muychi T Vang, Archito T. Tamayo, MS, Zhishuo Ou, MD, Alex Rollo, Liang Zhang, MD, PhD, Erin M Dominici, Elyse R Lopez, James Pham, Jack Wang, Lauren M Strickland, Michael Wang, MD, Richard J. Ford, MD, PhD

Blood (2013) 122 (21): 1274.

https://doi.org/10.1182/blood.V122.21.1274.1274

Published: 2013

Journal Articles

Biological Significance of the Immumoproteasome Subunits Mecl-1 and LMP-2 in Diffuse Large B-Cell Lymphoma.

Lan V Pham, PhD, Alex Rollo, Archito T. Tamayo, MS, John Lee, MD, Zhuang Zuo, MD, Ph.D, Luhong Sun, MD, PhD, Liang Zhang, MD, PhD, Zhishou Ou, MD, Luis E Fayad, MD, Michael Wang, M.D., Richard J. Ford, MD, PhD

Blood (2012) 120 (21): 2717.

https://doi.org/10.1182/blood.V120.21.2717.2717

Published: 2012

Journal Articles

Reversing Metabolic and Epigenetic Cellular Alterations to Overcome Chemo-Resistance in Aggressive B Cell Lymphomas

Kejie Zhang, MD, PhD, Lan V Pham, PhD, Archito T. Tamayo, MS, John Lee, MD, Jerry Bryant, M.S., Anas Younes, MD, Luis E Fayad, MD, David J Yang, Ph.D, Richard J. Ford, MD, PhD

Blood (2012) 120 (21): 1305.

https://doi.org/10.1182/blood.V120.21.1305.1305

Published: 2012

Journal Articles

Novel CRM-1 Inhibitors for Therapy In Mantle Cell Lymphoma

Kejie Zhang, MD, PhD, Lan V Pham, PhD, Liang Zhang, MD, PhD, Archito T. Tamayo, MS, Zhishuo Ou, MD, Dilara McCauley, PhD, Sharon Shacham, PhD, Michael Kauffman, MD, PhD, Richard J. Ford, MD, PhD, Michael Wang, MD

Blood (2011) 118 (21): 2734.

https://doi.org/10.1182/blood.V118.21.2734.2734

Published: 2011

Journal Articles

Carfilzomib, An Irreversible Proteasome Inhibitor, Induces Long-Term Growth Inhibition of Mantle Cell Lymphoma In Vivo,

Liang Zhang, MD, PhD, Jianfei Qian, PhD, Zhishuo Ou, MD, Luhong Sun, MD, PhD, Kejie Zhang, MD, PhD, Lan V Pham, PhD, Christopher J Kirk, PhD, Richard J. Ford, MD, PhD, Qing Yi, MD, PhD, Michael Wang, MD

Blood (2011) 118 (21): 3740.

https://doi.org/10.1182/blood.V118.21.3740.3740

Published: 2011

Journal Articles

Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target,

Sabine Ponader, PhD, Sriram Balasubramanian, PhD, Lan V Pham, PhD, Jun Chen, PhD, Archito T. Tamayo, MS, Michael Wang, MD, Susan O'Brien, MD, William G. Wierda, MD, PhD, Michael J Keating, MD, Richard J. Ford, MD, PhD, Jan A. Burger, MD, PhD

Blood (2011) 118 (21): 3688.

https://doi.org/10.1182/blood.V118.21.3688.3688

Published: 2011

Journal Articles

Smoothened (SMO), a G-Protein-Coupled Receptor (GPCR) Activated by Hedgehog Ligands, Modulates the Activity Levels of PI3K/AKT and NF-Kβ in Diffuse Large B-Cell Lymphoma,

Changju Qu, MD PhD, Yadong Liu, MD, Kranthi Kunkalla, MS, Nitin K Agarwal, PhD, Estelle Bourbon, MS, Lan V Pham, PhD, Richard J. Ford, MD, PhD, Rajesh Singh, PhD, Francisco Vega, MD, PhD

Blood (2011) 118 (21): 3483.

https://doi.org/10.1182/blood.V118.21.3483.3483

Published: 2011

Journal Articles

Single-Agent Bruton's Tyrosine Kinase (Btk) Inhibitor and Single-Agent Carfilzomib Induce Cell Apoptosis, Arrest Cell Growth and Downregulate NF-Kb Activity In Mantle Cell Lymphoma

Zhishuo Ou, MD, Lan V Pham, PhD, Liang Zhang, MD, PhD, Archito T. Tamayo, MS, John Lee, MD, Kejie Zhang, MD, PhD, Jacqueline Wang, James Phan, Changping Li, MD, Luhong Sun, MD, PhD, Richard J. Ford, MD, PhD, Michael Wang, MD

Blood (2011) 118 (21): 4971.

https://doi.org/10.1182/blood.V118.21.4971.4971

Published: 2011

NARROW

B-cell receptor–mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma

Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results

Cannabinoid Receptor Signaling As a Target for Personalized Therapy in Aggressive B Cell Lymphomas

Preclinical Evaluation of the Oral Proteasome Inhibitor Ixazomib in Diffuse Large B-Cell Lymphoma

The Tumor Microenvironment in Mantle Cell Lymphoma (MCL): Novel Targets to Overcome Chemo-Resistance in MCL

STAT3 Activation Is Preceded By Two Independent Pathways (BCR-BTK and IL6-JAK) in Mantle Cell Lymphoma

Anti-CD20 and B-Cell Receptor-Mediated Growth Inhibition and Apoptosis: A Preclinical Study of Ibrutinib and Rituximab Combination Therapy in Mantle Cell Lymphoma in Vitro and in Vivo

Carfilzomib, a Second-Generation Proteasome Inhibitor, In Combination With The Btk Inhibitor Ibrutinib As a Novel Therapeutic Regimen For Treating Double Hit DLBCL

Ibrutinib Overcomes Carfilzomib Resistance In Immunoproteasome-Deficient Mantle Cell Lymphoma

Targeting BCR Activated STAT3 By Ibrutinib In Mantle Cell Lymphoma

Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)

Selective Inhibitor Of Nuclear Exports (SINE) KPT-330 In Combination With The Novel Proteasome Inhibitor Carfilzomib As a Novel Therapeutic Regimen For Treating Aggressive B-Cell Lymphomas

The Role Of Mir-155 In Controlling Key Growth and Survival Pathways In ABC-Subtype DLBCL

Biological Significance of the Immumoproteasome Subunits Mecl-1 and LMP-2 in Diffuse Large B-Cell Lymphoma.

Reversing Metabolic and Epigenetic Cellular Alterations to Overcome Chemo-Resistance in Aggressive B Cell Lymphomas

Novel CRM-1 Inhibitors for Therapy In Mantle Cell Lymphoma

Carfilzomib, An Irreversible Proteasome Inhibitor, Induces Long-Term Growth Inhibition of Mantle Cell Lymphoma In Vivo,

Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target,

Smoothened (SMO), a G-Protein-Coupled Receptor (GPCR) Activated by Hedgehog Ligands, Modulates the Activity Levels of PI3K/AKT and NF-Kβ in Diffuse Large B-Cell Lymphoma,

Single-Agent Bruton's Tyrosine Kinase (Btk) Inhibitor and Single-Agent Carfilzomib Induce Cell Apoptosis, Arrest Cell Growth and Downregulate NF-Kb Activity In Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only